We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

323 hedge funds and large institutions have $8.13B invested in Jazz Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 108 increasing their positions, 115 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more funds holding in top 10

Funds holding in top 10: 6 → 11 (+5)

12% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 41

11% more capital invested

Capital invested by funds: $7.32B → $8.13B (+$808M)

0% more funds holding

Funds holding: 323 → 323 (0)

0.66% less ownership

Funds ownership: 90.8% → 90.14% (-0.66%)

6% less call options, than puts

Call options by funds: $31.7M | Put options by funds: $33.7M

6% less repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 115

Holders
323
Holders Change
–
Holders Change %
0%
% of All Funds
7.4%
Holding in Top 10
11
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+83.33%
% of All Funds
0.25%
New
46
Increased
108
Reduced
115
Closed
41
Calls
$31.7M
Puts
$33.7M
Net Calls
-$2.02M
Net Calls Change
+$33.4M

Top Buyers

1
PHS
PFM Health Sciences
California
+$167M
2
O
OrbiMed
New York
+$63.4M
3
TCIM
TIAA CREF Investment Management
New York
+$38.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$33.1M
5
Millennium Management
Millennium Management
New York
+$28.4M

Top Sellers

1
PI
Putnam Investments
Massachusetts
-$160M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$142M
3
Renaissance Technologies
Renaissance Technologies
New York
-$42M
4
AAMU
Amundi Asset Management US
Massachusetts
-$31.6M
5
American Century Companies
American Century Companies
Missouri
-$22.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
326
Stevens Capital Management
Pennsylvania
– -$5.09M -37,805 Closed
Group One Trading
327
Group One Trading
Illinois
– -$5.2M -35,444 Closed
HSA
328
Hussman Strategic Advisors
Maryland
– -$3.37M -25,000 Closed
VIA
329
Vident Investment Advisory
Georgia
– -$3.32M -24,636 Closed
GAM
330
Gotham Asset Management
New York
– -$2.31M -17,170 Closed
Tudor Investment Corp
331
Tudor Investment Corp
Connecticut
– -$1.93M -14,313 Closed
CG
332
Clinton Group
New York
– -$1.89M -14,018 Closed
Parallax Volatility Advisers
333
Parallax Volatility Advisers
California
– -$1.65M -12,246 Closed
ARTA
334
A.R.T. Advisors
New York
– -$1.31M -9,758 Closed
MF
335
Magnetar Financial
Illinois
– -$1.16M -8,599 Closed
DC
336
Diametric Capital
Massachusetts
– -$1.05M -7,788 Closed
HSBC Holdings
337
HSBC Holdings
United Kingdom
– -$884K -6,567 Closed
SGCA
338
Steel Grove Capital Advisors
Tennessee
– -$868K -6,450 Closed
Susquehanna International Group
339
Susquehanna International Group
Pennsylvania
– -$825K -5,623 Closed
EMG
340
Ellington Management Group
Connecticut
– -$633K -4,700 Closed
VI
341
Versor Investments
New York
– -$625K -4,644 Closed
Public Sector Pension Investment Board (PSP Investments)
342
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
– -$619K -4,600 Closed
Assenagon Asset Management
343
Assenagon Asset Management
Luxembourg
– -$567K -4,210 Closed
QT
344
Quantbot Technologies
New York
– -$556K -4,131 Closed
CIG
345
Consolidated Investment Group
Colorado
– -$355K -2,638 Closed
CB
346
Cadence Bank
Mississippi
– -$280K -2,077 Closed
FRM
347
Fox Run Management
Connecticut
– -$252K -1,874 Closed
BCM
348
Bayesian Capital Management
New York
– -$251K -1,862 Closed
Fisher Asset Management
349
Fisher Asset Management
Washington
– -$216K -1,606 Closed
IR
350
Invictus RG
Bermuda
– -$206K -1,533 Closed
11 12 13
14
15

JAZZ Hedge Fund Activity: Q1 2018 in Review

323 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2018, worth a combined $8.13B — up 11% from $7.32B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new JAZZ positions and 41 closed out — a net gain of 5 holders — while 108 added to existing stakes and 115 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $167M. The largest seller was Putnam Investments, cutting an estimated $160M.

  • 323 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $8.13B of Jazz Pharmaceuticals stock for Q1 2018, up 11% quarter-over-quarter.
  • 46 funds opened new Jazz Pharmaceuticals positions in Q1 2018 and 41 closed out, a net change of +5 holders.
  • The largest Jazz Pharmaceuticals buyer in Q1 2018 was PFM Health Sciences, an estimated $167M added.
  • The largest Jazz Pharmaceuticals seller in Q1 2018 was Putnam Investments, an estimated $160M sold.

Based on aggregated 13F filings for Q1 2018.